Based on the TIMER, we found that arm-level gain alteration of Notch3 was significantly associated with immunological of macrophages, CD4+ T cells, and Dendritic cells (Figure 7A); while on the mRNA levels, Notch3 expression is negatively related to B cells and positively correlated to the CD4+ T cells and dendritic cells (Figure 7B), which implies that Notch3 present a promising potential in assessing the efficacy of GBM immunotherapy. This evidence concerns the gene NOTCH3 and glioblastoma.